Ignite Creation Date:
2024-10-25 @ 7:50 PM
Last Modification Date:
2024-10-26 @ 3:37 PM
Study NCT ID:
NCT06550921
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-08-08
Brief Title:
Ablation of Oligometastasis Combined With Lenvatinib and PD-1 Inhibitor for Advanced Hepatocellular Carcinoma
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Ablation of Oligometastasis Combined With Lenvatinib and PD-1 Inhibitor for Advanced Hepatocellular Carcinoma A Multicenter Prospective Phase II Study
Status:
RECRUITING
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Ablation has been an effective approach for treating intrathoracic metastases However for hepatocellular carcinoma with oligometastasis ablation of metastases remains relatively unexplored
Detailed Description:
Systemic therapy is the standard treatment for advanced hepatocellular carcinoma HCC with metastasis However metastases with limited number oligometastasis can represent a subtype and transition point between localized disease and widespread metastases Thus eliminating metastases could be advantageous and beneficial to the prognosis if feasible and permitted Image-guided ablation therapy such as microwave ablation MWA radiofrequency ablation RFA and cryoablation has attracted great interest as a minimally invasive approach against intrathoracic metastases Recently ablation has been used on patients with pulmonary metastases from various cancers This technique yields high proportions of sustained complete responses and is associated with relatively low morbidity Thus we conduct this multicenter single arm study to explore the efficacy safety of lenvatinib and PD-1 inhibitor with metastases-directed ablation in advanced HCC This study focuses on the management of ablation of oligometastasis therapy combined with lenvatinib and PD-1 inhibitor This study aims to evaluate the survival benefits of ablating oligometastasis for advanced HCC
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None